Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Bruce E. Sands*, Laurent Peyrin-Biroulet, Edward V. Loftus, Silvio Danese, Jean-Frederic Colombel, Murat Toruner, Laimas Jonaitis, Brihad Abhyankar, Jingjing Chen, Raquel Rogers, Richard A. Lirio, Jeffrey D. Bornstein, Stefan Schreiber*, Marieke Pierik, VARSITY Study Group

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

INIS